Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine.
Amara, Rama Rao 1,3; Villinger, Francois 2; Altman, John D. 3; Lydy, Shari L. 1,3; O'Neil, Shawn P. 1,3; Staprans, Silvija I. 6; Montefiori, David C. 4; Xu, Yan 1; Herndon, James G. 1; Wyatt, Linda S. 5; Candido, Maria Angelito 1*; Kozyr, Natalia L. 6; Earl, Patricia L. 5; Smith, James M. 1,3; Ma, Hak-Ling 1,7+; Grimm, Bennett D. 2; Hulsey, Michael L. 3; Miller, Joseph 3; McClure, Harold M. 1; McNicholl, Janet M. 7; Moss, Bernard 5; Robinson, Harriet L. 1,3++
[Article] Science. 292(5514):69-74, April 6, 2001.

(Format: HTML)

Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.

Copyright (C) 2001 by the American Association for the Advancement of Science